Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000093971 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quantifying the impact of metronomic chemotherapy chemo-switch regimen and the sequencing of chemotherapy and radiotherapy on pancreatic ductal adenocarcinoma treatment.
J Theor Biol
February 2025
College of Information Engineering, Zhejiang University of Technology, Hangzhou, China. Electronic address:
Metronomic chemotherapy (MCT) is a novel chemotherapy approach characterized by a high-frequency, low-dose administration strategy. The "chemo-switch" regimen involves the sequential use of two dosing strategies: maximum tolerated dose (MTD) chemotherapy and MCT. For patients with pancreatic ductal adenocarcinoma (PDAC), selecting novel chemotherapy regimens appropriately according to their physical conditions may help address the challenges associated with MTD chemotherapy, such as excessive toxicity, prolonged tumor recovery, and suboptimal efficacy.
View Article and Find Full Text PDFMetronomic Chemotherapy in Breast Cancer as a Strategy to Deliver More Sustainable and Less Toxic Treatments: Time to Debunk the Myth?
Clin Breast Cancer
November 2024
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address:
Breast cancer is the most commonly diagnosed cancer in women, worldwide. With the increasing burden of breast cancer, the search for more tolerable and sustainable treatments is required, to result in broader access to cancer treatments. Metronomic chemotherapy defines the use of chemotherapy agents based on low-dose, continuous regimens, as opposed to traditional treatments administered for limited intervals, at higher dose.
View Article and Find Full Text PDFMetronomic Chemotherapy After Palliative Radiotherapy in Rare Soft Tissue Sarcomas: An Insight into Radiation Therapy and the Immune Response.
Indian J Surg Oncol
December 2024
Department of Radiation Oncology, J N Medical College, Belagavi, Karnataka India.
Article Synopsis
- Soft tissue sarcomas (STSs) make up less than 1% of all malignant tumors in humans, and treatment for metastatic STSs focuses on palliative care due to poor prognosis.
- A study evaluated the effectiveness of low-dose radiotherapy combined with metronomic therapy in 16 heavily treated patients with metastatic STSs, aiming to assess their response and quality of life.
- Results showed that 43.75% of patients achieved a partial response, and all reported improved quality of life compared to their previous treatment, demonstrating potential benefits of this combined approach in managing STSs.
Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers.
Mol Cancer
October 2024
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Article Synopsis
- Chitosan nanoparticles (NPs) are effective for delivering anticancer drugs by enhancing their solubility, permeability, and bioavailability without surfactants, enabling higher drug concentrations at tumor sites and reducing toxicity.
- These NPs can be engineered for slow drug release, which improves therapy effectiveness and reduces the need for frequent dosing.
- Targeting overexpressed folate receptors (FRs) on certain cancer cells with folate-modified chitosan NPs can improve treatment outcomes and predict therapy success, while also enhancing the oral absorption of poorly soluble drugs.
Intestinal ABC transporters: Influence on the metronomic cyclophosphamide-induced toxic effect in an obese mouse mammary cancer model.
Toxicol Appl Pharmacol
November 2024
Laboratorio de Fisiología Metabólica, Facultad de Ciencias Médicas, Universidad Nacional de Rosario. Rosario, Santa Fe, Argentina.; CONICET-Rosario. Rosario, Santa Fe, Argentina.. Electronic address:
Metronomic chemotherapy (MCT) is a cancer therapeutic approach characterized by low dose drug chronic administration and limited or null toxicity. Obesity-induced metabolic alterations worsen cancer prognosis and influence the intestinal biochemical barrier, altering the Multidrug resistance-associated protein 2 (Mrp2) and Multidrug resistance protein-1 (Mdr-1), efflux pumps that transport chemotherapeutic drugs. Obesity and cancer are frequent co-morbidities; thus, our aim was to evaluate the effectiveness and toxicity of MCT with cyclophosphamide (Cy) in obese mice with metabolic alterations bearing a mammary adenocarcinoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!